By GREGORY ZELLER // The National Institutes of Health is backing an early-stage Kings Park biotech’s quest for non-antibiotic-based COVID-19 treatments. CMTx Biotech has non-antimicrobials in its sights and a…
By GREGORY ZELLER // The National Institutes of Health has welcomed a rising Stony Brook biotech into its competitive Commercialization Accelerator Program. Traverse Biosciences, which is attempting to commercialize novel…
By GREGORY ZELLER // A biotech manufacturer with a 23-year history of servicing Stony Brook University researchers and startups is being evicted from the university’s Chemistry Building – and nobody…
By GREGORY ZELLER // When a new U.S. patent is your second-biggest announcement of the day, you’re probably in a good place. It’s all smiles (with healthy teeth, of course)…
By GREGORY ZELLER // First, healthy teeth for dogs … then a cancer cure for the world? Financially and otherwise, Traverse Biosciences enjoyed a strong 2016 – but it may…
By GREGORY ZELLER // It seems everyone wants a piece of TRB-N0224. Already being tested as a potential treatment for lung injuries and for periodontal disease in dogs and cats,…
Stony Brook-based biotech Traverse Biosciences will share a Department of Defense award with SUNY Upstate Medical University to fund a critical field test of Traverse’s leading drug candidate. The effectiveness…
By GREGORY ZELLER // A critical seed investment will help Traverse Biosciences commercialize pharmaceutical candidates licensed from the SUNY Research Foundation. The circa-2013 Stony Brook-based biotech has secured $500,000 in…
A Stony Brook-based bioscience startup has landed a long-awaited U.S. patent, marking a major step toward commercializing several novel drug candidates. The U.S. Patent and Trademark Office has granted Patent…
BY GREGORY ZELLER // Armed with a just-executed licensing agreement for a suite of anti-inflammatory drug therapies, two-year-old Traverse Biosciences is stepping up efforts to land the investors and strategic…